Which has preferable valuation and earnings, MGTX or QTTB?

Q32 Bio has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $81.39M 10.34 -$114.20M -$1.48 N/A Q32 Bio $53.74M 3.80 $29.82M $2.66 4.52

Is MGTX or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Q32 Bio's return on equity of 149.23% beat MeiraGTx's return on equity. Company Net Margins Return on Equity Return on Assets MeiraGTx -151.12% -1,065.47% -54.96% Q32 Bio N/A 149.23% 34.50%

Does the media prefer MGTX or QTTB?

In the previous week, Q32 Bio had 3 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Q32 Bio and 2 mentions for MeiraGTx. Q32 Bio's average media sentiment score of 1.57 beat MeiraGTx's score of 0.25 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, QTTB or IVA?

Q32 Bio has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 3.80 $29.82M $2.66 4.52 Inventiva $5.07M 160.19 -$400.67M N/A N/A

Is QTTB or IVA more profitable?

Q32 Bio's return on equity of 149.23% beat Inventiva's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% Inventiva N/A N/A N/A

Does the media favor QTTB or IVA?

In the previous week, Q32 Bio had 1 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Q32 Bio and 4 mentions for Inventiva. Q32 Bio's average media sentiment score of 1.57 beat Inventiva's score of 0.36 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inventiva 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ABUS or QTTB?

Q32 Bio has higher revenue and earnings than Arbutus Biopharma. Q32 Bio is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arbutus Biopharma $14.08M 59.49 -$33.50M $0.83 5.11 Q32 Bio $53.74M 3.80 $29.82M $2.66 4.52

Is ABUS or QTTB more profitable?

Arbutus Biopharma has a net margin of 83.95% compared to Q32 Bio's net margin of 0.00%. Q32 Bio's return on equity of 149.23% beat Arbutus Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Arbutus Biopharma 83.95% 129.32% 112.24% Q32 Bio N/A 149.23% 34.50%

Is QTTB or JANX more profitable?

Q32 Bio's return on equity of 149.23% beat Janux Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% Janux Therapeutics N/A -12.93% -12.23%

Does the media favor QTTB or JANX?

In the previous week, Q32 Bio had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Q32 Bio and 4 mentions for Janux Therapeutics. Q32 Bio's average media sentiment score of 1.57 beat Janux Therapeutics' score of 0.31 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, XNCR or QTTB?

Q32 Bio has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 6.74 -$91.92M -$2.29 N/A Q32 Bio $53.74M 3.80 $29.82M $2.66 4.52

Is XNCR or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Q32 Bio's return on equity of 149.23% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -177.10% -28.77% -20.52% Q32 Bio N/A 149.23% 34.50%

Q32 Bio (QTTB) Competitors

$12.03 -1.08 (-8.24%)

Closing price 04:00 PM Eastern

Extended Trading

$11.82 -0.21 (-1.70%)

As of 07:57 PM Eastern

Compare

QTTB vs. MGTX, IVA, ABUS, JANX, and XNCR

Should you buy Q32 Bio stock or one of its competitors? MarketBeat compares Q32 Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Q32 Bio include MeiraGTx (MGTX), Inventiva (IVA), Arbutus Biopharma (ABUS), Janux Therapeutics (JANX), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

How does Q32 Bio compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

MeiraGTx currently has a consensus price target of $25.83, indicating a potential upside of 184.20%. Q32 Bio has a consensus price target of $13.50, indicating a potential upside of 12.22%. Given MeiraGTx's stronger consensus rating and higher possible upside, equities analysts plainly believe MeiraGTx is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 7.5% of MeiraGTx shares are held by company insiders. Comparatively, 40.0% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Q32 Bio has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	10.34	-$114.20M	-$1.48	N/A
Q32 Bio	$53.74M	3.80	$29.82M	$2.66	4.52

In the previous week, Q32 Bio had 3 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Q32 Bio and 2 mentions for MeiraGTx. Q32 Bio's average media sentiment score of 1.57 beat MeiraGTx's score of 0.25 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MeiraGTx has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Q32 Bio has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Q32 Bio's return on equity of 149.23% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Q32 Bio	N/A	149.23%	34.50%

Summary

MeiraGTx and Q32 Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Inventiva?

Q32 Bio (NASDAQ:QTTB) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Q32 Bio presently has a consensus price target of $13.50, indicating a potential upside of 12.22%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 323.42%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

In the previous week, Q32 Bio had 1 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Q32 Bio and 4 mentions for Inventiva. Q32 Bio's average media sentiment score of 1.57 beat Inventiva's score of 0.36 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inventiva	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Q32 Bio has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Q32 Bio has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	3.80	$29.82M	$2.66	4.52
Inventiva	$5.07M	160.19	-$400.67M	N/A	N/A

Q32 Bio's return on equity of 149.23% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Inventiva	N/A	N/A	N/A

Summary

Q32 Bio beats Inventiva on 8 of the 14 factors compared between the two stocks.

How does Q32 Bio compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Q32 Bio had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Q32 Bio and 0 mentions for Arbutus Biopharma. Q32 Bio's average media sentiment score of 1.57 beat Arbutus Biopharma's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Arbutus Biopharma	Neutral
Q32 Bio	Very Positive

Q32 Bio has higher revenue and earnings than Arbutus Biopharma. Q32 Bio is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	59.49	-$33.50M	$0.83	5.11
Q32 Bio	$53.74M	3.80	$29.82M	$2.66	4.52

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 40.0% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arbutus Biopharma presently has a consensus target price of $5.00, indicating a potential upside of 17.92%. Q32 Bio has a consensus target price of $13.50, indicating a potential upside of 12.22%. Given Arbutus Biopharma's higher possible upside, research analysts plainly believe Arbutus Biopharma is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Arbutus Biopharma has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Q32 Bio's net margin of 0.00%. Q32 Bio's return on equity of 149.23% beat Arbutus Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Q32 Bio	N/A	149.23%	34.50%

Summary

Q32 Bio beats Arbutus Biopharma on 10 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Janux Therapeutics?

Q32 Bio (NASDAQ:QTTB) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

In the previous week, Q32 Bio had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Q32 Bio and 4 mentions for Janux Therapeutics. Q32 Bio's average media sentiment score of 1.57 beat Janux Therapeutics' score of 0.31 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Janux Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Q32 Bio has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market.

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 40.0% of Q32 Bio shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Q32 Bio's return on equity of 149.23% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Janux Therapeutics	N/A	-12.93%	-12.23%

Q32 Bio has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	3.80	$29.82M	$2.66	4.52
Janux Therapeutics	$10M	82.38	-$113.62M	-$1.84	N/A

Q32 Bio presently has a consensus price target of $13.50, suggesting a potential upside of 12.22%. Janux Therapeutics has a consensus price target of $45.85, suggesting a potential upside of 239.35%. Given Janux Therapeutics' higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Q32 Bio beats Janux Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Q32 Bio compare to Xencor?

Xencor (NASDAQ:XNCR) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Q32 Bio has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	6.74	-$91.92M	-$2.29	N/A
Q32 Bio	$53.74M	3.80	$29.82M	$2.66	4.52

Xencor presently has a consensus price target of $24.50, suggesting a potential upside of 114.72%. Q32 Bio has a consensus price target of $13.50, suggesting a potential upside of 12.22%. Given Xencor's higher probable upside, equities research analysts plainly believe Xencor is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Q32 Bio had 5 more articles in the media than Xencor. MarketBeat recorded 5 mentions for Q32 Bio and 0 mentions for Xencor. Q32 Bio's average media sentiment score of 1.57 beat Xencor's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Xencor	Neutral
Q32 Bio	Very Positive

Xencor has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Q32 Bio has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Q32 Bio's return on equity of 149.23% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Q32 Bio	N/A	149.23%	34.50%

31.3% of Q32 Bio shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 40.0% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Q32 Bio beats Xencor on 10 of the 15 factors compared between the two stocks.

Get Q32 Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTTB vs. The Competition

Export

Metric	Q32 Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$222.30M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	7.58	18.93	23.75	23.75
Price / Sales	3.80	173.93	479.99	83.74
Price / Cash	8.65	51.45	26.99	37.25
Price / Book	3.53	8.04	10.28	6.78
Net Income	$29.82M	$23.89M	$3.57B	$337.51M
7 Day Performance	3.17%	-5.97%	-1.43%	-2.72%
1 Month Performance	124.02%	2.78%	3.27%	1.87%
1 Year Performance	533.16%	36.26%	23.37%	26.61%

Q32 Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTTB Q32 Bio	4.58 of 5 stars	$12.03 -8.2%	$13.50 +12.2%	+590.0%	$222.30M	$53.74M	7.58	39	Positive News
MGTX MeiraGTx	2.9977 of 5 stars	$9.24 -5.7%	$25.83 +179.6%	+50.0%	$855.72M	$79.76M	N/A	300	Positive News
IVA Inventiva	3.567 of 5 stars	$4.09 -14.3%	$16.56 +304.8%	+14.5%	$849.52M	$4.48M	N/A	100	Gap Down High Trading Volume
ABUS Arbutus Biopharma	1.6749 of 5 stars	$4.26 -4.9%	$5.00 +17.4%	+22.1%	$841.51M	$191.45M	5.13	90	Positive News
JANX Janux Therapeutics	3.4284 of 5 stars	$13.78 -4.4%	$45.85 +232.7%	-49.0%	$840.30M	$10M	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTTB) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Q32 Bio (QTTB) Competitors